Fibroblast growth factor-21 (FGF21) analogs as possible treatment options for diabetes mellitus in veterinary patients
Publication date
2023-01-09
Authors
Corbee, Ronald
van Everdingen, Dion L
Kooistra, Hans
Penning, Louis
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
Fibroblast growth factors (FGFs) are involved in numerous metabolic processes. The endocrine subfamily of FGFs, consisting of FGF19, FGF21, and FGF23, might have beneficial effects in the treatment of diabetes mellitus (DM) and/or obesity. The analog with the greatest potential, FGF21, lowers blood glucose levels, improves insulin sensitivity, and induces weight loss in several animal models. In this review we summarize recent (pre)clinical findings with FGF21 analogs in animal models and men. Furthermore, possible applications of FGF21 analogs for pets with DM will be discussed. As currently, information about the use of FGF21 analogs in pet animals is scarce.
Keywords
FGF, diabetes, endocrine, glucose, insulin, metabolism, obesity, General Veterinary, SDG 3 - Good Health and Well-being
Citation
Corbee, R J, van Everdingen, D L, Kooistra, H S & Penning, L C 2023, 'Fibroblast growth factor-21 (FGF21) analogs as possible treatment options for diabetes mellitus in veterinary patients', Frontiers in Veterinary Science, vol. 9, 1086987, pp. 1-8. https://doi.org/10.3389/fvets.2022.1086987